Sarepta Therapeutics (NASDAQ:SRPT) reported second quarter earnings that beat analyst expectations, but revenue fell short and the company provided weaker-than-expected guidance for fiscal year 2025, sending shares down about 11% in after-hours trading.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,